ArticleCancer medicine2026
Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Survival of U.S. Military Service Members with Hodgkin Lymphoma by Post-9/11 Deployment Status.Cancer research communications · 2026Article
- From Cure to Combat: Deployment After Lymphoma.Journal of clinical medicine · 2026Article
- Beyond the Battlefield: Lymphoma Outcomes in Post-9/11 Service Members and Veterans.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLymphoma risk varies by demographics, environmental/occupational exposures, and medical care between active-duty service members (ADSM) and the general US population (GUSP). This study compared age-adjusted incidence rates and trends of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between these groups.
methodsData were obtained from the Department of War's Central Cancer Registry and the National Cancer Institute's Surveillance, Epidemiology, and End Results database, including individuals aged 18-59 diagnosed with lymphoma between 1998 and 2014. Incidence rate ratio (IRR) and 95% CIs were calculated to compare the incidence of HL and NHL between ADSM and GUSP, with analyses stratified by sex, race, age, stage, and histology.
resultsLymphoma incidence was lower in ADSM than GUSP (HL: 0.93 [0.86, 1.00]; NHL: 0.82 [0.77, 0.88]); specifically, for men (HL: 0.89 [0.82, 0.97]; NHL: 0.69 [0.64, 0.74]), White (HL: 0.87 [0.80, 0.95]; NHL: 0.80 [0.73, 0.86]), and Black individuals (HL: 0.82 [0.68, 0.99]; NHL: 0.61 [0.51, 0.73]). Incidence was lower among ADSM aged 18-39 (HL: 0.91 [0.84, 0.99]; NHL: 0.74 [0.68, 0.81]), but similar at ages 40-59. ADSM had lower HL (early-stage: 0.86 [0.77, 0.96]; nodular lymphocyte predominant: 0.88 [0.80, 0.97]) and NHL (early stage: 0.86 [0.77, 0.96]; advanced stage: 0.87 [0.78, 0.97]; diffuse large B-cell: 0.65 [0.58, 0.74]; other histologies: 0.83 [0.74, 0.93]) incidence.
conclusionLymphoma incidence was lower in ADSM than GUSP, particularly among men and younger individuals. Based on prior literature, this may be related to the healthier status of ADSM and earlier detection and treatment of medical conditions that can predispose to lymphoma. Diminished differences between the two populations for older individuals may reflect cumulated military-related exposures within a generally healthier population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.